EUVIMEDEUVIMED entdecken
Multizentrische Studie

Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis

Gianluca Avallone iD, Andrea Bombelli iD, Luca Valtellini iD, Gianluca Tavoletti iD, Benedetta Galli, Mariateresa Rossi, Martina Maurelli, Giampiero Girolomoni, Luigi Gargiulo iD, Alessandra Narcisi, Francesca di Vico, Maddalena Napolitano und 35 weitere

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llaf302 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Gianluca Avallone und 46 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Prurigo, Janus Kinase Inhibitors, Sulfonamides, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prurigo nodularis (PN) is a debilitating skin condition. When inadequate disease control is achieved or other systemic therapies are contraindicated, Janus kinase inhibitors (JAKis) may be considered, although real-world evidence remains limited.

Objectives

To investigate clinical findings and treatment outcomes among patients diagnosed with PN and treated with JAKis in a real-world setting.

Methods

Retrospective cohort study across 23 Italian tertiary referral hospitals. Patients with PN were eligible if aged ≥ 18 years and had received a JAKi with a minimum follow-up of 12 weeks. The primary outcome was defined as the proportion of patients achieving a reduction of ≥ 4 points from baseline in the Peak Pruritus Numerical Rating Scale score. Key secondary outcomes included the rates of patients reaching a significant reduction in Investigator Global Assessment of Prurigo Nodularis Stage (IGA PN-S) and Investigator Global Assessment of Prurigo Nodularis Activity (IGA PN-A) scores.

Results

Of the total, 71 patients met the inclusion criteria. At week 16, the proportion of patients achieving the primary outcome was 94% for upadacitinib [n = 52/55; 95% confidence interval (CI) 87–100%], 83% for abrocitinib (n = 10/12; 95% CI 52–98%) and 100% for baricitinib (n = 4/4; 95% CI 40–100%), with results sustained at week 24. An IGA PN-A score of 0/1 was achieved in 90% of patients treated with upadacitinib and abrocitinib and in 50% of those on baricitinib by week 24. Improvements were observed across all other secondary outcomes assessed, with no safety concerns reported.

Conclusions

This study suggests that JAKis can achieve clinically meaningful outcomes in PN irrespective of atopic background, supporting their use across diverse patient profiles. Further research is warranted to validate these observations and explore their long-term effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrurigoJanus Kinase InhibitorsSulfonamidesHeterocyclic Compounds, 3-RingHumansRetrospective StudiesMaleFemaleMiddle AgedTreatment OutcomeAgedPyrimidinesAdultAzetidinesPurinesItalyAged, 80 and over

Substanzen

Janus Kinase InhibitorsPyrimidinesupadacitinibSulfonamidesabrocitinibHeterocyclic Compounds, 3-RingAzetidinesPurines

Autor:innen und Institutionen

  • Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

ORCID-Profile: Gianluca Avallone, Andrea Bombelli, Luca Valtellini, Gianluca Tavoletti, Luigi Gargiulo, Francesca Barei, Luca Stingeni

Zitieren

APA

Avallone, G., Bombelli, A., Valtellini, L., Tavoletti, G., Galli, B., Rossi, M., Maurelli, M., Girolomoni, G., Gargiulo, L., Narcisi, A., di Vico, F., Napolitano, M., Lazzeri, L., Calabrese, L., Caccavale, S., Balato, A., Barei, F., Calzari, P., Foti, C., …, & Ferrucci, S. M. (2025). Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf302

Vancouver

Avallone G, Bombelli A, Valtellini L, Tavoletti G, Galli B, Rossi M, et al. Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf302

BibTeX
@article{Avallone2025,
  author = {Avallone, Gianluca and Bombelli, Andrea and Valtellini, Luca and Tavoletti, Gianluca and Galli, Benedetta and Rossi, Mariateresa and Maurelli, Martina and Girolomoni, Giampiero and Gargiulo, Luigi and Narcisi, Alessandra and di Vico, Francesca and Napolitano, Maddalena and Lazzeri, Laura and Calabrese, Laura and Caccavale, Stefano and Balato, Anna and Barei, Francesca and Calzari, Paolo and Foti, Caterina and Trave, Ilaria and Cozzani, Emanuele and Rongioletti, Franco and Lenti, Sveva and Gurioli, Carlotta and Nettis, Eustachio and Caroppo, Francesca and Errichetti, Enzo and Bonzano, Laura and Gori, Niccolò and Peris, Ketty and Lembo, Serena and Del Regno, Laura and Esposito, Maria and Fargnoli, Maria C and Savoia, Paola and Esposto, Elia and Giuffrida, Roberta and Guarneri, Fabrizio and Patruno, Cataldo and Pezzolo, Elena and Stingeni, Luca and Hansel, Katharina and Mastorino, Luca and Ortoncelli, Michela and Ribero, Simone and Marzano, Angelo V and Ferrucci, Silvia M},
  title = {Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llaf302}
}
Kostenlos starten →